The US private equity investor SK Capital Partners has acquired Swixx BioPharma Group, a leading global full-service partner in the distribution of biopharmaceutical products. The investment values the company at more than EUR 1.5 billion.
COBALT, together with lead counsel Bär & Karrer, advised SK Capital Partners on the transaction. The legal due diligence covered one of Swixx BioPharma Group’s Lithuanian subsidiaries and ensured compliance with Lithuanian legislation.
SK Capital Partners is a New York–based private investment firm focused on the life sciences, specialty materials, and ingredients sectors. The Swixx BioPharma Group is a leading global full-service partner in biopharmaceutical distribution, with a strong presence across Central and Eastern Europe and Latin America.
In this transaction, the team was led by Partner Elijus Burgis, and the project was coordinated by Associate Aurimas Drumstas. The team also included Specialist Counsel Sandra Sidoraitė, Managing Associate Renata Vasiliauskiene, Senior Associates Juras Žymančius and Ieva Pukelienė, Associates Ieva Milkamanaviciute and Dovilė Platakytė, Assistant Lawyers Bernard Balcevič and Vitold Dvorak.
Leading experts
